Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05877560 · ClinicalTrials.gov registry record · NA
Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency
A NA study of Convergence Insufficiency, sponsored by Midwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05877560: Recruiting NA study of Convergence Insufficiency, sponsored by Midwestern University.
NCT05877560 is a NA study of Convergence Insufficiency that is actively recruiting participants, run by Midwestern University. The registered enrollment target is 150 participants, above the 101-participant average among 6 other Convergence Insufficiency trials with a reported enrollment target (49% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05877560, a NA study of Convergence Insufficiency, is actively recruiting participants, sponsored by Midwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1. Can non-invasive brain stimulation shorten the treatment time of office-based vergence/accommodative therapy for convergence insufficiency? 2. Is non-invasive brain stimulation alone just as effective as office-based vergence/accommodative therapy in treating convergence insufficiency? The investigators hypothesize that non-invasive brain stimulation will shorten the treatment time from 12 weeks to 8 weeks of office-based vergence/accommodative therapy and that non-invasive brain stimulation alone would be equally effective as office-based vergence/accommodative therapy in improving symptomatic convergence insufficiency. Participants will be randomized into one of three treatment groups: 1. Non-invasive brain stimulation with office-based vergence/accommodative therapy. 2. Sham stimulation with office-based vergence/accommodative therapy. 3. Non-invasive brain stimulation only. Researchers will compare baseline measurements of near point of convergence (NPC) and positive fusional vergence (PFV) to post-treatment measurements for each group.
Primary Outcome
A change in the NPC break and recovery values measured in centimeters (cm) from baseline after treatment.
Conditions Studied
Interventions
- DEVICE Anodal-Transcranial Direct Current Stimulation
- BEHAVIORAL Office-Based Vergence/Accommodative Therapy
- DEVICE Sham Transcranial Direct Current Stimulation
Study Locations (1)
Illinois
- Midwestern University Eye Institute - Downers Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT05877560 shows while recruiting
NCT05877560 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 6 other Convergence Insufficiency trials with a reported enrollment target (49% higher).
The record links to 1 condition, with Convergence Insufficiency appearing as the primary indexed condition, and to 3 interventions - of which Anodal-Transcranial Direct Current Stimulation is the first listed.
NCT05877560 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05877560 about?
NCT05877560 is a clinical study titled "Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency". The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are: 1. Can non-invasive brain stimulation short...
What is the current status of trial NCT05877560?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-03-01. Estimated completion is 2028-12-31.
What conditions does trial NCT05877560 study?
This clinical trial studies the following conditions: Convergence Insufficiency.
What interventions are being tested in trial NCT05877560?
The interventions under investigation include: Anodal-Transcranial Direct Current Stimulation (DEVICE), Office-Based Vergence/Accommodative Therapy (BEHAVIORAL), Sham Transcranial Direct Current Stimulation (DEVICE).
Who is sponsoring clinical trial NCT05877560?
This trial is sponsored by Midwestern University, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05877560 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Convergence Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
RECRUITING · NA
-
Neural Mechanism of Vision Therapy for Patients With Convergence Insufficiency
COMPLETED · NA
-
Home-based Vision Therapy
RECRUITING · Phase 1
-
Effectiveness of Virtual Reality Vision Therapy - VERVE
RECRUITING · Early Phase 1
-
A Prospective Observational Study of Adult Strabismus
COMPLETED
-
Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI